|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parekh DJ, Bochner BH and Dalbagni G:
Superficial and muscle-invasive bladder cancer: Principles of
management for outcomes assessments. J Clin Oncol. 24:5519–5527.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Porten SP, Leapman MS and Greene KL:
Intravesical chemotherapy in non-muscle-invasive bladder cancer.
Indian J Urol. 31:297–303. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Herr HW, Dotan Z, Donat SM and Bajorin DF:
Defining optimal therapy for muscle invasive bladder cancer. J
Urol. 177:437–443. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Babjuk M, Oosterlinck W, Sylvester R,
Kaasinen E, Böhle A, Palou-Redorta J and Rouprêt M: European
Association of Urology (EAU): EAU guidelines on non-muscle-invasive
urothelial carcinoma of the bladder, the 2011 update. Eur Urol.
59:997–1008. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oosterlinck W, Kurth KH, Schröder F,
Bultinck J, Hammond B and Sylvester R: A prospective European
Organization for Research and Treatment of Cancer Genitourinary
Group randomized trial comparing transurethral resection followed
by a single intravesical instillation of epirubicin or water in
single stage Ta, T1 papillary carcinoma of the bladder. J Urol.
149:749–752. 1993.PubMed/NCBI
|
|
7
|
Yu R, Yu BX, Chen JF, Lv XY, Yan ZJ, Cheng
Y and Ma Q: Anti-tumor effects of Atractylenolide I on bladder
cancer cells. J Exp Clin Cancer Res. 35:402016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ronsin C, Muscatelli F, Mattei MG and
Breathnach R: A novel putative receptor protein tyrosine kinase of
the met family. Oncogene. 8:1195–1202. 1993.PubMed/NCBI
|
|
9
|
Park YL, Lee GH, Kim KY, Myung E, Kim JS,
Myung DS, Park KJ, Cho SB, Lee WS, Jung YD, et al: Expression of
RON in colorectal cancer and its relationships with tumor cell
behavior and prognosis. Tumori. 98:652–662. 2012.PubMed/NCBI
|
|
10
|
Feres KJ, Ischenko I and Hayman MJ: The
RON receptor tyrosine kinase promotes MSP-independent cell
spreading and survival in breast epithelial cells. Oncogene.
28:279–288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheng HL, Liu HS, Lin YJ, Chen HH, Hsu PY,
Chang TY, Ho CL, Tzai TS and Chow NH: Co-expression of RON and MET
is a prognostic indicator for patients with transitional-cell
carcinoma of the bladder. Br J Cancer. 92:1906–1914. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Catenacci DV, Cervantes G, Yala S, Nelson
EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Brägelmann J,
Seiwert T, et al: RON (MST1R) is a novel prognostic marker and
therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol
Ther. 12:9–46. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ren X, Daa T, Yada N, Kashima K, Fujitomi
Y and Yokoyama S: Expression and mutational status of RON in
neoplastic lesions of the breast: Analysis of MSP/RON signaling in
ductal carcinoma in situ and invasive ductal carcinoma. APMIS.
120:358–367. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang MH, Lee W, Luo YL, Weis MT and Yao
HP: Altered expression of the RON receptor tyrosine kinase in
various epithelial cancers and its contribution to tumourigenic
phenotypes in thyroid cancer cells. J Pathol. 213:402–411. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang MH, Kurtz AL and Chen Y:
Identification of a novel splicing product of the RON receptor
tyrosine kinase in human colorectal carcinoma cells.
Carcinogenesis. 21:1507–1512. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Eckerich C, Schulte A, Martens T, Zapf S,
Westphal M and Lamszus K: RON receptor tyrosine kinase in human
gliomas: Expression, function, and identification of a novel
soluble splice variant. J Neurochem. 109:969–980. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ma Q, Zhang K, Guin S, Zhou YQ and Wang
MH: Deletion or insertion in the first
immunoglobulin-plexin-transcription (IPT) domain differentially
regulates expression and tumorigenic activities of RON receptor
Tyrosine Kinase. Mol Cancer. 9:3072010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yao HP, Zhou YQ, Zhang R and Wang MH:
MSP-RON signalling in cancer: Pathogenesis and therapeutic
potential. Nat Rev Cancer. 13:466–481. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Prislei S, Mariani M, Raspaglio G,
Mozzetti S, Filippetti F, Ferrandina G, Scambia G and Ferlini C:
RON and cisplatin resistance in ovarian cancer cell lines. Oncol
Res. 19:13–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yao HP, Zhou YQ, Ma Q, Guin S, Padhye SS,
Zhang RW and Wang MH: The monoclonal antibody Zt/f2 targeting RON
receptor tyrosine kinase as potential therapeutics against tumor
growth-mediated by colon cancer cells. Mol Cancer. 10:82–93. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu XM, Wang D, Shen Q, Chen YQ and Wang
MH: RNA-mediated gene silencing of the RON receptor tyrosine kinase
alters oncogenic phenotypes of human colorectal carcinoma cells.
Oncogene. 23:8464–8474. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yao HP, Zhuang CM, Zhou YQ, Zeng JY, Zhang
RW and Wang MH: Oncogenic variant RON160 expression in breast
cancer and its potential as a therapeutic target by small molecule
tyrosine kinase inhibitor. Curr Cancer Drug Targets. 13:686–697.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hsu PY, Liu HS, Cheng HL, Tzai TS, Guo HR,
Ho CL and Chow NH: Collaboration of RON and epidermal growth factor
receptor in human bladder carcinogenesis. J Urol. 176:2262–2267.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guin S, Yao HP and Wang MH: RON receptor
tyrosine kinase as a target for delivery of chemodrugs by antibody
directed pathway for cancer cell cytotoxicity. Mol Pharm.
7:386–397. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guin S, Ma Q, Padhye S, Zhou YQ, Yao HP
and Wang MH: Targeting acute hypoxic cancer cells by
doxorubicin-immunoliposomes directed by monoclonal antibodies
specific to RON receptor tyrosine kinase. Cancer Chemother
Pharmacol. 67:1073–1083. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li Z, Yao H, Guin S, Padhye SS, Zhou YQ
and Wang MH: Monoclonal antibody (mAb)-induced down-regulation of
RON receptor tyrosine kinase diminishes tumorigenic activities of
colon cancer cells. Int J Oncol. 37:473–482. 2010.PubMed/NCBI
|
|
27
|
Padhye SS, Guin S, Yao HP, Zhou YQ, Zhang
R and Wang MH: Sustained expression of the RON receptor tyrosine
kinase by pancreatic cancer stem cells as a potential targeting
moiety for antibody-directed chemotherapeutics. Mol Pharm.
8:2310–2319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Follenzi A, Bakovic S, Gual P, Stella MC,
Longati P and Comoglio PM: Cross-talk between the proto-oncogenes
Met and Ron. Oncogene. 19:3041–3049. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Peace BE, Hill KJ, Degen SJ and Waltz SE:
Cross-talk between the receptor tyrosine kinases Ron and epidermal
growth factor receptor. Exp Cell Res. 289:317–325. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Clark PE, Agarwal N, Biagioli MC,
Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel
TM, Lele SM, et al: National Comprehensive Cancer Network (NCCN):
Bladder cancer. J Natl Compr Canc Netw. 11:446–475. 2013.PubMed/NCBI
|
|
31
|
Babjuk M, Burger M, Zigeuner R, Shariat
SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A,
Redorta J Palou, et al: European Association of Urology: EAU
guidelines on non-muscle-invasive urothelial carcinoma of the
bladder: Update 2013. Eur Urol. 64:639–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Logan-Collins J, Thomas RM, Yu P, Jaquish
D, Mose E, French R, Stuart W, McClaine R, Aronow B, Hoffman RM, et
al: Silencing of RON receptor signaling promotes apoptosis and
gemcitabine sensitivity in pancreatic cancers. Cancer Res.
70:1130–1140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yao HP, Luo YL, Feng L, Cheng LF, Lu Y, Li
W and Wang MH: Agonistic monoclonal antibodies potentiate
tumorigenic and invasive activities of splicing variant of the RON
receptor tyrosine kinase. Cancer Biol Ther. 5:1179–1186. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jin X, Zhu Z and Shi Y: Metastasis
mechanism and gene/protein expression in gastric cancer with
distant organs metastasis. Bull Cancer. 101:E1–E12. 2014.PubMed/NCBI
|
|
35
|
Wagh PK, Peace BE and Waltz SE:
Met-related receptor tyrosine kinase Ron in tumor growth and
metastasis. Adv Cancer Res. 100:1–33. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Camp ER, Liu W, Fan F, Yang A, Somcio R
and Ellis LM: RON, a tyrosine kinase receptor involved in tumor
progression and metastasis. Ann Surg Oncol. 12:273–281. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Feng L, Yao HP, Wang W, Zhou YQ, Zhou J,
Zhang R and Wang MH: Efficacy of anti-RON antibody Zt/g4-drug
maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for
targeted colorectal cancer therapy. Clin Cancer Res. 20:6045–6058.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Morgan DO: Cyclin-dependent kinases:
Engines, clocks, and microprocessors. Annu Rev Cell Dev Biol.
13:261–291. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Murray AW and Marks D: Can sequencing shed
light on cell cycling? Nature. 409:844–846. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Connell-Crowley L, Elledge SJ and Harper
JW: G1 cyclin-dependent kinases are sufficient to initiate DNA
synthesis in quiescent human fibroblasts. Curr Biol. 8:65–68. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Vermeulen K, Van Bockstaele DR and
Berneman ZN: The cell cycle: A review of regulation, deregulation
and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chung CY, Park YL, Song YA, Myung E, Kim
KY, Lee GH, Ki HS, Park KJ, Cho SB, Lee WS, et al: Knockdown of RON
inhibits AP-1 activity and induces apoptosis and cell cycle arrest
through the modulation of Akt/FoxO signaling in human colorectal
cancer cells. Dig Dis Sci. 57:371–380. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Song YA, Park YL, Kim KY, Myung E, Chung
CY, Cho SB, Lee WS, Jung YD, Kweon SS and Joo YE: RON is associated
with tumor progression via the inhibition of apoptosis and cell
cycle arrest in human gastric cancer. Pathol Int. 62:127–136. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Brunelle JK and Letai A: Control of
mitochondrial apoptosis by the Bcl-2 family. J Cell Sci.
122:437–441. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nakashima T, Miura M and Hara M:
Tetrocarcin A inhibits mitochondrial functions of Bcl-2 and
suppresses its anti-apoptotic activity. Cancer Res. 60:1229–1235.
2000.PubMed/NCBI
|
|
46
|
Wong RS: Apoptosis in cancer: From
pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011.
View Article : Google Scholar : PubMed/NCBI
|
